A detailed history of Sherbrooke Park Advisers LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 18,466 shares of ACAD stock, worth $315,214. This represents 0.07% of its overall portfolio holdings.

Number of Shares
18,466
Previous 22,872 19.26%
Holding current value
$315,214
Previous $372 Million 23.59%
% of portfolio
0.07%
Previous 0.07%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.14 - $19.14 $66,706 - $84,330
-4,406 Reduced 19.26%
18,466 $284 Million
Q2 2024

Aug 14, 2024

SELL
$14.62 - $18.42 $183,159 - $230,765
-12,528 Reduced 35.39%
22,872 $372 Million
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $629,766 - $1.09 Million
35,400 New
35,400 $655 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.